Report Overview

The global Primary Hyperoxaluria drugs market size stood at around USD 0.10 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. The condition often results in end stage renal disease (ESRD), which is a life-threatening condition that prevents the kidneys from filtering fluids and waste products from the body effectively

It is estimated to affect 1 in 58,000 individuals worldwide. Type 1 is the most common form, accounting for approximately 80 percent of cases. Types 2 and 3 each account for about 10 percent of cases



Market Drivers

Increasing prevalence is driving demand for primary hyperoxaluria drugs around the world. However, with rising awareness and increased diagnostic facilities, demand for primary hyperoxaluria drugs is expected to be triggered in emerging economies such as China and India. High investment in research & development by leading industry participants is expected to open new growth window for them. With strong research and development initiative, most of the companies are focusing on innovative and cost-effective drug development